Galvanize Therapeutics Raises $130 Million Series D To Expand PEF Ablation Platform

Galvanize Therapeutics has closed an oversubscribed $130 million Series D financing to expand its commercial business, generate clinical evidence and develop additional pulsed electric field technologies.

HealthQuest Capital led the round. Olympus Innovation Ventures and Braidwell joined as new investors alongside existing backers Sofinnova Partners, Norwest, Elevage Medical Technologies, Ally Bridge Group, Perceptive Advisors, Janus Henderson Investors, Longaeva Partners, Fidelity Management & Research Company and T. Rowe Price Associates.

HealthQuest Founder and Managing Partner Dr. Garheng Kong will join Galvanize’s board.

The Redwood City, California-based company is commercializing its Aliya pulsed electric field platform in the United States while developing applications in oncology and chronic disease.

Recent milestones include FDA clearance and commercial introduction of the Aliya EX Generator, increased physician adoption and more than 4,000 procedures performed.

The company has enrolled over 300 patients in its PROPEL registry. Its scientific evidence base includes more than 40 peer-reviewed publications examining mechanisms, outcomes and potential applications.

Proceeds will support further Aliya expansion, clinical research, advancement of RheOx therapy for chronic bronchitis and development of next-generation products.

Aliya EX delivers short-duration, high-voltage electrical energy to induce nonthermal regulated cell death during surgical soft-tissue ablation.

Preclinical and early clinical findings suggest the technology may promote antigen release that could activate an immune response. Its effectiveness in inducing an immune response that benefits patients has not been established.

The financing supports both the existing commercial platform and development-stage programs, with evidence generation remaining an important part of the strategy.

Chairman and CEO Doug Godshall said the investment provides resources to build on adoption and commercial execution while pursuing broader applications across oncology and chronic disease.

KEY QUOTES

“This financing marks an important inflection point for Galvanize. We’ve built a strong foundation with Aliya, demonstrating the potential of our PEF technology through growing physician adoption, commercial execution, and an expanding body of clinical evidence. This investment positions us to accelerate our growth and pursue our broader vision of expanding the impact of PEF across oncology and chronic disease. We’re grateful for the continued confidence of our investors as we enter this next phase of growth.”

Doug Godshall, Chairman And CEO Of Galvanize Therapeutics

“We have followed Galvanize’s progress closely over the years and are thrilled to back the company as it enters its next phase of growth. Galvanize has built a differentiated PEF platform with the potential to meaningfully advance care in interventional oncology and pulmonology. We are excited to partner with the exceptional team as they expand the reach and impact of their innovative technology.”

Garheng Kong, MD, PhD, Founder And Managing Partner Of HealthQuest Capital